NBE-Therapeutics

OverviewSuggest Edit

NBE-Therapeutics engages in the development of “next-generation” antibody drug conjugates (ADCs) leveraging its proprietary technology platforms for therapeutic antibody and site-specific conjugation technologies. NBE-Therapeutics has the goal to develop best-in-class ADC product candidates until clinical proof-of-concept in patients.

TypePrivate
Founded2012
HQBasel, CH
Websitenbe-therapeutics.com

Key People/Management at NBE-Therapeutics

Ulf Grawunder

Ulf Grawunder

Founder and CEO
Jim O'Leary

Jim O'Leary

Interim Chief Medical Officer
Wouter Verhoeven

Wouter Verhoeven

MSc, Chief Business Officer
Roger R. Beerli

Roger R. Beerli

PhD, Chief Scientific Officer
Show more

NBE-Therapeutics Office Locations

NBE-Therapeutics has an office in Basel
Basel, CH (HQ)
Hochbergerstrasse 60C
Show all (1)

NBE-Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

NBE-Therapeutics total Funding

$23.6 m

NBE-Therapeutics latest funding size

$20.45 m

Time since last funding

3 years ago

NBE-Therapeutics investors

NBE-Therapeutics's latest funding round in November 2016 was reported to be $20.5 m. In total, NBE-Therapeutics has raised $23.6 m
Show all financial metrics

NBE-Therapeutics Online and Social Media Presence

Embed Graph

NBE-Therapeutics News and Updates

WuXi Biologics y NBE-Therapeutics anuncian una colaboración completa para el desarrollo y la producción de ADC

SHANGHÁI y BASILEA, Suiza, 10 de abril de 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), empresa con una plataforma tecnológica de productos biológicos de acceso abierto líder a escala mundial que ofrece soluciones integrales para el descubrimiento, el desarrollo y la...

WuXi Biologics und NBE-Therapeutics kündigen umfassende Partnerschaft bei AWK-Entwicklung und -Herstellung an

SCHANGHAI und BASEL, Schweiz, April 10, 2019 /PRNewswire/ -- WuXi Biologics („WuXi Bio") (2269.HK), ein führender weltweiter Anbieter von Open-Access-Technologieplattformen für Biologika, der Komplettlösungen für die Entdeckung, Entwicklung und Herstellung von Biologika anbietet, und...

WuXi Biologics et NBE-Therapeutics annoncent un vaste partenariat de développement et de fabrication d'ADC

SHANGHAI et BÂLE, Suisse, 9 avril 2019 /PRNewswire/ -- WuXi Biologics (« WuXi Bio ») (2269.HK), société de premier plan mondial pour sa plateforme technologique en accès libre pour produits biologiques proposant des solutions de bout en bout pour la découverte, la mise au point et la...

WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

SHANGHAI and BASEL, Switzerland, April 8, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and NBE-Therapeutics (NBE), a...

NBE-Therapeutics Frequently Asked Questions

  • When was NBE-Therapeutics founded?

    NBE-Therapeutics was founded in 2012.

  • Who are NBE-Therapeutics key executives?

    NBE-Therapeutics's key executives are Ulf Grawunder, Jim O'Leary and Wouter Verhoeven.

  • Who are NBE-Therapeutics competitors?

    Competitors of NBE-Therapeutics include Araris Biotech, LGC Biosearch Technologies and Fate Therapeutics.

  • Where is NBE-Therapeutics headquarters?

    NBE-Therapeutics headquarters is located at Hochbergerstrasse 60C, Basel.

  • Where are NBE-Therapeutics offices?

    NBE-Therapeutics has an office in Basel.

  • How many offices does NBE-Therapeutics have?

    NBE-Therapeutics has 1 office.